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Abstract: The triple test is a second trimester screening test used to identify those pregnant 
women who should be offered a diagnostic test to identify whether their fetus has an aneuploidy. 
It was first described in 1988, but has largely been superseded by newer tests either conducted 
earlier in the first trimester (ie, the combined test, using ultrasound measurement of nuchal trans-
lucency, pregnancy-associated plasma protein A, and human chorionic gonadotrophin [hCG]) 
or in the second trimester (ie, the quadruple test, using α-fetoprotein, hCG, uE3, and inhibin). 
These newer tests have been introduced because they offer greater detection and lower screen 
positive results thereby enhancing diagnosis rates, while decreasing the risk of iatrogenic harm 
caused by the invasive testing required when collecting suitable sample tissue. Noninvasive 
alternatives to the triple test have been identified, but these have not been adopted despite 13 
years of development. It is likely, therefore, that the triple test (or variants thereof) will continue 
to be used in routine antenatal care for the foreseeable future.
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Introduction
The triple test is one of a range of screening tests that are used to identify pregnant 
women whose fetus is likely to be affected by trisomy 21 (Down syndrome) and who 
should then be offered a diagnostic test. All of the tests similar to the triple test are 
based on the same mathematical principle (Bayes theorem) and work by combining 
a prior probability derived from maternal age at expected date of delivery with a 
  likelihood ratio usually based on two multivariate Gaussian distribution functions.1 
This combination results in a reasonably accurate risk estimate of the probability that 
the fetus has Down syndrome.2 Women whose risk exceeds a specified cutoff are then 
offered a diagnostic test (ie, amniocentesis or chorionic villus biopsy), which allows 
a cytogenetic diagnosis to be determined. This may be done either by cell culture and 
karyotyping or by fluorescent in situ hybridization (FISH).
The triple test is used only in the second trimester of pregnancy and now has a range 
of competitors (Table 1). As one of the first entrants into the serum screening arena, it is 
therefore legitimate to question whether it remains relevant more than 20 years after it was 
developed. There are a number of factors that affect the decision about which screening 
test to use: screening test effectiveness; cost-effectiveness; cost-benefit/cost-hazard.
How reliable are screening protocols?
When screening, reliability is measured by assessing the effectiveness of differ-
ent screening protocols by measuring the detection rate and corresponding screen International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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  positive rate. To allow comparison, it is usual to fix the 
screen positive rate and assess the detection rate using a 
computer model rather than gleaning this directly from 
patient data.   Different studies generate different basic data 
sets and modeling can generate controversy over the value of 
different protocols. The original description of the triple 
test estimated that   adding unconjugated estriol to a double 
test increased the detection rate from 55% to approximately 
60% for a 5% screen positive rate.3 A later estimate claimed 
that for ultrasound-dated pregnancies, the double test had 
a detection rate of 58% and the triple test 67% for a screen 
positive rate of 5% and suggested that without ultrasound 
there was only a 4% difference in detection rates between 
the two tests.4 In the early days of Down syndrome screen-
ing, it was often felt by laboratory managers that the slight 
increment in detection was not worth the extra reagent and 
staff costs, leading them to opt for the double test.
Table 2 shows estimates of detection rates at specific 
screen positive rates for different screening strategies and 
makes it clear that the triple test is now outclassed by other 
test variations.
Logical choices and consumer behavior
The triple test is, thus, no longer the most effective screening 
test for antenatal Down syndrome and consequently many 
national guidelines recommend other screening tests instead. 
In practice, however, it is still in common use, at least in 
the United Kingdom (UK). There must, therefore, be other 
  factors that influence choice of screening tests to use.
Over the last 10 years in the UK, the triple test was the 
test routinely offered.5 It would be logical to expect there 
would be a move to the quadruple test because this would 
allow improved detection and lower screen positive rates 
without the need to redesign the way in which patient   services 
were provided. This did not occur, partly because the only 
  commercially available assay for inhibin-A (the fourth 
  analyte in the quadruple test) was not suitable for use in a 
routine laboratory because it was insufficiently stable and 
the intrabatch assay variation was excessive (coefficient of 
variation [CV], 17%). This lead to an excessively high screen 
positive rate when compared with the computer simulation 
models of quadruple screening.6 Consequently, although 
superior in a research setting, the quadruple test was not 
practical for use in a routine laboratory. More recently, the 
inhibin assay has been automated, leading to substantial 
improvement in performance. In the UK, this has not resulted 
in wide uptake of the extra test.
Another reason for the reluctance to add extra tests is the 
law of diminishing returns meaning as each extra analyte is 
added to the basic double test the incremental improvement 
in detection rate is less. Furthermore, there is a tendency 
for the newer tests to be more expensive so the cost-benefit 
equation becomes harder to justify. In the UK National Health 
Service (NHS) centrally-funded health service model, it is 
difficult to persuade the commissioners to pay yet more for 
a tiny improvement in a screening program when there are 
pressing health needs that must be addressed elsewhere.
Yet another factor was consumer behavior. In the UK, 
the standard service provided by the NHS was the second 
trimester triple test. One of my roles is the Director of 
  Prenatal Screening for the South Yorkshire Sub-Regional 
Down’s Screening Programme run by the laboratory of the 
Northern General Hospital, Sheffield. It was obvious from the 
pattern of cytogenetic reports in our regular audit   meetings 
that a significant proportion of patients were exercising 
their   consumer choice and paying for private first trimester 
Table 2 Detection rates for different antenatal Down syndrome 
screening strategies from the SURUSS study41
Test name DR @  
SPR = 1%
DR @  
SPR = 3%
DR @  
SPR = 5%
Double test 
(using free-β hCG)
46% 63% 71%
Triple test  
(using free-β hCG)
56% 70% 77%
Quadruple test 
(using free-β hCG)
66% 79% 84%
Combined test  66% 78% 83%
Serum integrated test  77% 86% 90%
Integrated test  84% 91% 93%
Abbreviations:  SURUSS,  serum  urine  and  ultrasound  screening  study;  DR, 
detection rate; SPR, screen positive rate.
Table 1 Strategies for antenatal Down syndrome screening
Test name Used in Analytes
Double test3 Second trimester AFP + hCG (total or free-β) 
Triple test3 Second trimester As double test +  
unconjugated estriol
Quadruple test37 Second trimester As triple test (using free-β  
hCG) + inhibin-A
Combined test38 First trimester Ultrasound measurement of 
NT + PAPP-A + free-β hCG
Serum integrated 
test39
Both first and  
second trimester
PAPP-A (first trimester) + 
quadruple test (or triple 
test)
Integrated test39 Both first and  
second trimester
As serum integrated test + 
NT in first trimester
Contingent  
test40
Both first and  
second trimester
Dependent on structure of  
contingent screen chosen
Abbreviations:  AFP,  α-fetoprotein;  hCG,  human  chorionic  gonadotropin;  NT, 
nuchal translucency; PAPP-A, pregnancy-associated plasma protein A. International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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screening because they wanted to know the result earlier 
than would be possible under the NHS scheme. This trend 
is reversing, as first trimester screening is now provided in 
the Sheffield NHS screening program. Since patients wanted 
earlier screening, it was clear that first trimester screening 
had to be made available with all of the consequent changes 
to the antenatal care package that this introduction process 
entailed.
Clearly, women did not choose the first trimester test on 
the basis of effectiveness, cost-effectiveness, and   cost-benefit/ 
hazard ratios. Rather, an ultrasound test is far more personally 
interactive and, in addition to allowing the first view of the 
baby, gives an immediate answer as to whether the baby has 
any major problems. It is, therefore, entirely understandable 
that first trimester testing was popular with patients.
A further question that could be raised is why use the 
obviously less effective first trimester combined test, when 
the integrated test appears to be far more effective? Here, 
there were good practical reasons why the integrated test 
was not introduced. For instance, the integrated test uses 
information collected in both trimesters of pregnancy and 
requires a wait until all of that data has been collected before 
calculating the risk estimate. This means there is the need 
to ensure that women attend on more than one occasion for 
the screening test to be performed, increasing the risk of 
dropout when appointments are missed. Furthermore, there 
is a delay during which information that may allow an early 
diagnostic test to be carried out is withheld. This delay has 
been criticized as being ethically unacceptable.7
An alternative method that was suggested to avoid the 
ethical objections to the integrated test was the contingent 
screen. In this test, the first trimester screening results were 
revealed and those at very low risk were excluded from 
the next stage while those at very high risk were offered a 
  diagnostic test. Those in the middle were offered a second 
stage test in the second trimester and, depending on the result, 
were offered a diagnostic test. A trial of the acceptability 
and effectiveness of a contingent screen found that 16.7% 
of women booked too late to be offered the first trimester 
stage of the process, but the majority of women entering the 
screening process completed it, thereby proving that fears of 
high dropout rates were unfounded Most women were happy 
to be offered contingent screening.8
International perspective
Internationally, Down syndrome screening practices vary. 
In the UK, standards have been imposed on all laboratories 
carrying out Down syndrome screening by the National 
Health Service Fetal Anomaly Screening Programme (NHS 
FASP) which specify that “all Down’s syndrome screening 
programmes must meet a target detection rate of greater than 
75%, for a false positive rate of less than 3%, by 2007”.9 The 
FASP model of best practice10 recommends that this should 
be achieved using the combined test, the integrated test, or 
the serum integrated test for women who present in the first 
trimester, and the quadruple test for women who present in 
the second trimester. The FASP annual report for 2006–20085 
shows that in 2007, the predominant screening strategy 
was the triple test with a significant number of   centers 
using combined testing and a smaller proportion providing 
  quadruple testing. The most recent report11 indicates that 
113 of the 152 Primary Care Trusts (the fund-holding units 
of the NHS) in England will have changed to the combined 
screen by April 2010 and the remainder do not yet have firm 
plans to change. This does not, however, mean that these 
units have abandoned the triple screen since they need to 
have an alternative for patients who book too late for first 
trimester testing.
In the United States (US), it was only in 2007 that the 
American College of Gynecologists recommended that all 
women should be eligible for screening regardless of   maternal 
age, whereas previously only women over the age of 35 were 
automatically offered genetic counseling and   amniocentesis 
or chorionic villus sampling.12 A recent survey of US 
  obstetricians showed that 95% now offered Down syndrome 
screening to all patients, with 70%   offering first trimester 
screening and 86% offering the quadruple screen.13
In Australia, the combined test is recommended for 
the first trimester and the quadruple test for the second 
  trimester.14 Similarly, in Canada the Society of Obstetricians 
and Gynecologists recommend this protocol.15
Is the triple test relevant?
It is clear that the triple test is now becoming increasingly 
irrelevant as a clinical test because other variants on the test 
have been mandated by national quality standards aiming to 
reduce the number of diagnostic tests required and to further 
decrease the iatrogenic risk to unaffected pregnancies.
The future
ethical challenges
While of decreasing clinical relevance, the triple test still 
has great importance for the future. Antenatal screening 
for Down syndrome was one of the first examples of mass 
population testing to prevent a genetic disorder. The test 
was introduced as an extension of earlier neural tube defect International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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(NTD)   screening programs which were designed to detect 
conditions that caused significant disability. Consequently, 
Down syndrome screening was introduced as a clinical 
  service with research into test improvement being carried 
out on routinely collected data. This meant that the research 
was generally carried out without any review by a research 
ethics committee. In 2003, a survey of research ethics com-
mittees in the UK found that if ethical approval had been 
sought to allow research into Down syndrome screening, it 
is likely it would have been refused.16 In general, these ethics 
committees felt that screening for a condition that caused 
some learning deficiencies and minor reduction in life span 
was no more acceptable than screening to prevent children 
suffering the “socially embarrassing physical characteristics 
of red hair and freckles”.16
Ethics can be a difficult area in which to research because 
there is no ‘correct’ answer to any question. Surveys of 
  individuals have revealed there is more reluctance to consider 
termination of a fetus because it has Down syndrome than 
if it were affected by spina bifida or hemophilia.17 Surveys 
of physicians have demonstrated greater reluctance to ter-
minate hemophilia-than Downs syndrome-affected fetuses18 
and opinions of Anglophone and Francophone physicians 
differ.19 A survey of Lutheran pastors demonstrated that 
only 23% considered Down syndrome to be a sufficiently 
serious condition to warrant termination.20 The situation is 
further complicated by the fact that pregnant women regard 
the prospect of a Down syndrome-affected birth to be more 
burdensome than a procedure-related miscarriage21 and by 
studies that show that women’s views about screening are 
affected by available resources, their own feelings about hav-
ing a child with Down syndrome, their moral beliefs, family 
and social influences, perceptions of their own health, and 
any difficulty in becoming pregnant.22
Opinions also vary between countries: 33% of   respondents 
in a survey in Russia indicated that they favored compulsory 
termination of pregnancy if testing identified a genetic 
  disorder in the fetus and Russians were more in favor 
of prenatal screening, selective termination, and genetic 
manipulation to improve a child’s intelligence or reduce the 
probability of homosexuality.23
In the UK and most countries, Down syndrome   screening 
was introduced as an optional test that women had to agree 
to have done, not a test that they had to opt out of. A recent 
report on the prevalence of thyroid dysfunction in   pregnancy 
in a particular region of China stated that the study blood 
samples were from a random selection of cases from a 
Down syndrome screening cohort. It was known to avoid 
any   possible collection biases because it is state law that 
women must accept antenatal testing for Down syndrome.24 
This may not be the national standard throughout China, but 
does raise important ethical questions. If Down syndrome 
screening becomes a compulsory element in antenatal care, 
what does this presage for future reproductive autonomy? 
We must also question whether Down syndrome screening 
is the thin end of a wedge; how far will screening be taken 
and what is the limit of acceptability?25
Alternative screening tests
Fetal cells in maternal blood
Many years before the introduction of Down syndrome 
screening, it was discovered that fetal cells could be identified 
in the maternal circulation and used to identify fetal gender.26 
After the introduction of Down syndrome screening, a great 
amount of effort was made to develop extraction methods 
that would allow fetal cells to be purified from maternal 
blood, which would allow noninvasive prenatal diagnosis. 
As a result, dozens of research teams worked on projects to 
extract erythroblasts, leukocytes, trophoblasts, etc.27 Unfor-
tunately, while fetal cells have been successfully extracted 
in a research setting, this process has not been introduced 
into routine practice.
Cell-free DNA in maternal serum
In 1997, the presence of cell-free fetal DNA in maternal 
serum was identified.28 This was thought to offer another 
prospect for noninvasive prenatal testing. Thirteen years 
later, methods for antenatal rhesus typing29 and fetal 
gender30 have been described. A routine application for 
RhD typing has been tested and proven to be effective.31 
Experimental methods for using this technology for Down 
syndrome   testing have been reported and include: single 
nucleotide   polymorphism allelic ratios;32 circulating pla-
cental   messenger ribonucleic acid (mRNA) analysis;33 and 
epigenetic-genetic chromosome-dosage.34 It is worth noting 
that these experimental methods are mostly all described by 
the same research group, however.
Thus, 13 years after this method for screening was devel-
oped, no routine application for aneuploidy detection has yet 
been described. This should be contrasted with the triple test 
which was first described in 1988.3 The first routine screen-
ing program in the UK NHS was introduced in 1990 and 
its effectiveness during its first full year of operation (Feb 
1990–1991) was reported in 1993.35 Therefore, it only took two 
years of research indicating that antenatal serum screening for 
Down syndrome could be effective before the technique was International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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introduced as a routine screening test.   Cell-free DNA was iden-
tified 13 years ago and, although several techniques to allow it 
to be used for diagnosis have been described, none have been 
taken into routine use. We cannot, therefore, predict whether 
serum DNA will ever become a routine test: To become 
accepted, it has to supplant already established tests and the 
technical difficulties associated with amplification-based test-
ing (which makes sample purity/ lack of contamination vital) 
must be overcome. Finally, there are ethical implications of 
DNA and RNA testing which must be considered.36
Conclusions
The triple test was first described in 19883 and rapidly 
entered routine use as an antenatal screen for Down syn-
drome.35 As the years have progressed, it has been super-
seded by newer variations (eg, first trimester combined 
testing and the quadruple test), which have been recom-
mended in national guidelines, not because the triple test 
has been unreliable, rather because the other tests have 
proven more effective in terms of greater detection with 
lower screen positive rates.
The triple test remains relevant because it is the   foundation 
upon which current antenatal screening tests for Down syn-
drome are rooted. It is also important because of the ethical 
dilemmas it creates. Where does the limit of acceptability for 
screening lie? Most countries currently allow their citizens 
to have reproductive autonomy, but the introduction of Down 
syndrome screening has lowered the barriers to other forms of 
genetic screening tests. It becomes possible that reproductive 
autonomy may be threatened by economic factors that may 
favor compulsory screening. Thus, Down syndrome screening 
will continue to be controversial for many years to come.
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